Context Therapeutics missed quarterly earnings, dropping its stock, but maintained a "buy" rating.

Context Therapeutics reported a quarterly loss of $0.22 per share, missing analysts' estimates by $0.11, leading to a $0.14 drop in its stock price to $1.95. Despite the earnings miss, HC Wainwright maintained a "buy" rating with a $6.00 price target. The biopharmaceutical company focuses on developing treatments for solid tumors, including its lead candidate CTIM-76.

November 09, 2024
3 Articles